Multiple myeloma (MM) is a common hematological neoplasm consisting of malignant plasma cells, which expand in the bone marrow. A potential key signal in the evolution of MM is hepatocyte growth factor (HGF), which acts as a potent para-and/or autocrine growth-and survival factor for MM cells. Proteolytic conversion of HGF into its active form is a critical limiting step in HGF/MET signaling. Here, we show that malignant MM plasma cells convert HGF into its active form and secrete HGF-activator (HGFA), a serine protease specific for HGF activation. By using serine protease inhibitors and neutralizing antibodies, we demonstrate that HGFA produced by the MM cells is responsible for their ability to catalyze HGF activation. We therefore suggest that autocatalyzation of HGF conversion by MM cells is an important step in HGF/MET-induced myeloma growth and survival, which may have implications for the management of this incurable form of cancer.
Introduction
The unrestrained growth of tumor cells is generally attributed to mutations in essential growth control genes, but tumor cells are also influenced by signals from the environment. In MM, the factors and signals coming from the bone marrow (BM) microenvironment are possibly even essential for the growth of the tumor cells. As targets for intervention, these signals may be equally important as mutated oncogenes 1, 2 . Recent studies have identified HGF as a potential key signal in the evolution of MM. HGF has a domain structure and proteolytic mechanism of activation similar to that of the blood serine protease plasminogen, but lacks protease activity. Instead, via its tyrosine kinase receptor MET, HGF induces complex biological responses in target cells, including motility, growth, and morphogenesis. Whereas a functional HGF/MET pathway is indispensable for mammalian development, uncontrolled MET signaling, provoked by MET activating mutations or MET amplification and overexpression, is oncogenic, and has been implicated in the development and progression of a variety of human cancers [3] [4] [5] . In MMs, HGF exerts strong proliferative and anti-apoptotic effects via the RAS/MAPK and PI3K/PKB pathways 6, 7 . Within the BM microenvironment, stromal cells present a paracrine source of HGF 8 , however, an autocrine HGF/MET loop has also been reported in myeloma cells 9, 10 . Furthermore, in a recent gene-profiling study HGF was the only significantly overexpressed growth factor in MM 11 , while high serum HGF levels in MM patients predict unfavorable prognosis 12 
.
Upon secretion, HGF normally retains its 90-kDa single-chain (sc) precursor form, which is probably cell surface or extracellular matrix associated. For biological function however, proteolytic conversion of scHGF to the heterodimeric active form is essential 13 .
Although the role of HGF in tumor progression has attracted much attention, the molecular mechanisms underlying HGF activation in tumor tissue remain largely unexplored.
Plasminogen activators, particularly uPA and factor XIIa have been shown to activate scHGF, although at low rates 14, 15 . More recently, hepatocyte growth factor activator (HGFA), a factor XIIa-related serine protease with an efficient HGF-activating activity, was identified [15] [16] [17] . This enzyme is secreted by the liver as an inactive zymogen [15] [16] [17] and has recently also 
Material and Methods

Antibodies
Monoclonal antibodies were: anti-HGFA , A-1 (IgG1) and P1-4 (IgG1) 15 ; anti-factor XIIa, OT-2 (IgG1) (Sanquin, Amsterdam, The Netherlands); IgG1 control antibody (DAKO, Glostrup, Denmark); anti-hepatocyte growth factor activator inhibitor-1 (HAI-1) 18 . Polyclonal antibodies used were goat anti-human HGF (R&D Systems, Abington, UK); R-phycoerythrin-conjugated goat anti-mouse (Southern Biotechnology, Birmingham, AL); horseradish peroxidase (HRP)-conjugated rabbit anti-mouse (DAKO); HRP-conjugated goat-anti-rabbit (DAKO).
MM cells, cell cultures, transfectants and conditioned medium
MM cell lines UM1, UM3, UM6, L363, NCI-H929, OMP-1, LME-1, and XG-1 were grown as described previously 6, 7 . COS7 cells were transiently transfected with the mammalian expression vector pCIneo-HGFA containing full-length HGFA 18 using the DEAE-dextran method. Conditioned medium was obtained as described previously 
Immunoprecipitation and western blot analysis
Immunoprecipitation and western blotting was performed as described 6 . For the HGF activation assay, serum free cultured cells were lysed in the absence of protease inhibitors since these affect the function of HGFA. For immunoprecipitation of HGFA, the lysates were incubated with the monoclonal antibody A-1 pre-coupled to Protein G-Sepharose beads (Pharmacia Biotech, Uppsala, Sweden). The precipitates were washed three times with lysis buffer and were resolved by sodium dodecylsulfate polyacrylamide gel electrophoresis under reducing conditions. The immunoblots were stained with anti-HGF or anti-HGFA and detected with HRP-conjugated swine anti-goat and HRP-conjugated rabbit anti-mouse respectively.
Assay for HGF activation
HGF activation was assayed as described previously 18 . In brief, single chain HGF (R&D Systems) was incubated with either intact MM cells, with MM conditioned medium or with HGFA immunoprecipitated from MM conditioned medium. To study activation by cells, these were washed thoroughly and incubated serum free overnight. Subsequently, the cells were washed and 10 5 cells were incubated in 0.1 ml medium containing scHGF (1µg/ml) for the time indicated in the presence or absence of 4 units/ml thrombin (Sigma Aldrich Chemie GmbH, Germany). For HGF activation, 20 µl conditioned medium or sample containing immunoprecipitated HGFA were pretreated with 1 unit of thrombin and added to 0.1µg scHGF. Inhibitor studies were done in the presence of aprotinin (2TIU/ml), leupeptin (500µg /ml), C1-inhibitor (kindly provided by E. Hack, Sanquin, Amsterdam, The Netherlands) or neutralizing antibody P1-4 (40µg/ml).
Immunocytochemistry
HGFA expression in MM cell lines and primary myeloma cells was studied on aceton-fixed cytospins with mAb A-1 using biotin-conjugated rabbit as second step. The reaction was developed with 3,3-amino-9-ethylcarbazole (Sigma) and cytospins were counterstained with
Haematoxylin. COS-7 cells transfected with a construct containing HGFA were used as positive control, and appropriate isotype antibodies as negative controls.
Flow Cytometry
For the determination of HGFA expression, monoclonal antibody PI-4 and secondary antibody PE-conjugated goat anti mouse Ig (Southern Biotechnology) were used. For intracellular HGFA staining, the MM cell lines were fixed with 2% paraformaldehyde and 
Results and discussion
Proteolytic activation of HGF in the extracellular milieu is a critical limiting step in HGF/MET signaling. We observed that the MM cell lines NCI-H929, XG-1 and OMP-1 cells were all able to process scHGF to its active form ( Figure 1A) . The processing of scHGF either required or was greatly enhanced by the addition of thrombin and was completely inhibited by the serine protease inhibitors leupeptin ( Figure 1A) and aprotinin (not shown). Since HGFA is a serine protease specifically activated by thrombin 17, 20 , these observations suggested that the HGF processing activity might be due to HGFA. 6, 7 . In addition, since HGF is a potent angiogenic factor 2, 3, 21 , it may also contribute to tumor angiogenesis which has recently been identified as an important process in the progression and prognosis of MM 
